- Home
- SNDX vs GDYN Comparison
SNDX vs GDYN Comparison
Compare SNDX & GDYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNDX
- GDYN
- Stock Information
- Founded
- SNDX 2005
- GDYN 2006
- Country
- SNDX United States
- GDYN United States
- Employees
- SNDX N/A
- GDYN N/A
- Industry
- SNDX Biotechnology: Pharmaceutical Preparations
- GDYN Computer Software: Prepackaged Software
- Sector
- SNDX Health Care
- GDYN Technology
- Exchange
- SNDX Nasdaq
- GDYN Nasdaq
- Market Cap
- SNDX 1.1B
- GDYN 1.1B
- IPO Year
- SNDX 2016
- GDYN N/A
- Fundamental
- Price
- SNDX $9.48
- GDYN $11.51
- Analyst Decision
- SNDX Strong Buy
- GDYN Strong Buy
- Analyst Count
- SNDX 11
- GDYN 4
- Target Price
- SNDX $35.91
- GDYN $18.75
- AVG Volume (30 Days)
- SNDX 1.8M
- GDYN 658.9K
- Earning Date
- SNDX 07-31-2025
- GDYN 07-31-2025
- Dividend Yield
- SNDX N/A
- GDYN N/A
- EPS Growth
- SNDX N/A
- GDYN 322.00
- EPS
- SNDX N/A
- GDYN 0.13
- Revenue
- SNDX $43,722,000.00
- GDYN $371,169,000.00
- Revenue This Year
- SNDX $426.77
- GDYN $21.02
- Revenue Next Year
- SNDX $98.31
- GDYN $13.95
- P/E Ratio
- SNDX N/A
- GDYN $90.74
- Revenue Growth
- SNDX N/A
- GDYN 18.72
- 52 Week Low
- SNDX $8.58
- GDYN $9.53
- 52 Week High
- SNDX $25.07
- GDYN $25.50
- Technical
- Relative Strength Index (RSI)
- SNDX 36.85
- GDYN 33.35
- Support Level
- SNDX $11.00
- GDYN $11.36
- Resistance Level
- SNDX $11.83
- GDYN $11.80
- Average True Range (ATR)
- SNDX 0.58
- GDYN 0.37
- MACD
- SNDX -0.11
- GDYN -0.01
- Stochastic Oscillator
- SNDX 10.31
- GDYN 13.56
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
About GDYN Grid Dynamics Holdings Inc.
Grid Dynamics Holdings Inc is a provider of technology consulting, platform and product engineering, and advanced analytics services. The company delivers tailored solutions in several industry verticals like Tech, Media and Telecom, Retail, Finance and Consumer Packaged goods (CPG)/manufacturing. The company derives maximum revenue from Retails. Geographically company earns revenue from North America, Europe and other regions.